Floatz logo

Adebelimab

PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

447 Active assets in the PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Adebelimab is also rated in:

small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →
cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →